Analysis about the influence on the fetus infected with parvovirus B19 using amniotic erythropoietin and troponin-T

Yoshida, Masashi; Matsuda, Hideo; Yoshinaga, Yosuke; Asai, Kazuhiko; Kawashima, Akitsugu; Sei, Kiguna; Horii, Miho; Nakanishi, Atsushi; Soyama, Hiroaki; Furuya, Kenichi

doi:10.1007/s00404-013-2815-y

Cited by 7 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 896 articles identified through the search, 87 were assessed for their eligibility (Table S2) and 35 studies were eventually included in the systematic review (Figure and Table ). These 35 studies included 611 fetuses affected by PB19 infection based on serological or virological confirmation or presence of signs of fetal anemia, such as hydrops, on ultrasound in fetuses with infected mothers. The definition of fetal hydrops in each included study is reported in Table S3.…”

Section: Resultsmentioning

confidence: 99%

Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta‐analysis

Bascietto

Liberati

Murgano

et al. 2018

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta‐analysis

Bascietto

Liberati

Murgano

et al. 2018

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

“…The mechanisms of filtration (transport) of cardiospecific Tn molecules from the bloodstream to other biological fluids are not investigated, and, accordingly, these possibilities of non-invasive diagnostics have not been validated. Thus, the study of the metabolic pathway of cardiospecific Tns and potential factors influencing it is a relatively large and poorly studied area for further research that is needed to optimize diagnostics and validate new diagnostic capabilities( Stefanovic and Loukovaara, 2005 ; Zhu et al, 2007 ; Van Mieghem et al, 2010 ; Yoshida et al, 2013 ; Blohm et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Metabolic Pathway of Cardiospecific Troponins: From Fundamental Aspects to Diagnostic Role (Comprehensive Review)

Chaulin

2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Many molecules of the human body perform key regulatory functions and are widely used as targets for the development of therapeutic drugs or as specific diagnostic markers. These molecules undergo a significant metabolic pathway, during which they are influenced by a number of factors (biological characteristics, hormones, enzymes, etc.) that can affect molecular metabolism and, as a consequence, the serum concentration or activity of these molecules. Among the most important molecules in the field of cardiology are the molecules of cardiospecific troponins (Tns), which regulate the processes of myocardial contraction/relaxation and are used as markers for the early diagnosis of ischemic necrosis of cardiomyocytes (CMC) in myocardial infarction (MI). The diagnostic value and diagnostic capabilities of cardiospecific Tns have changed significantly after the advent of new (highly sensitive (HS)) detection methods. Thus, early diagnostic algorithms of MI were approved for clinical practice, thanks to which the possibility of rapid diagnosis and determination of optimal tactics for managing patients with MI was opened. Relatively recently, promising directions have also been opened for the use of cardiospecific Tns as prognostic markers both at the early stages of the development of cardiovascular diseases (CVD) (arterial hypertension (AH), heart failure (HF), coronary heart disease (CHD), etc.), and in non-ischemic extra-cardiac pathologies that can negatively affect CMC (for example, sepsis, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), etc.). Recent studies have also shown that cardiospecific Tns are present not only in blood serum, but also in other biological fluids (urine, oral fluid, pericardial fluid, amniotic fluid). Thus, cardiospecific Tns have additional diagnostic capabilities. However, the fundamental aspects of the metabolic pathway of cardiospecific Tns are definitively unknown, in particular, specific mechanisms of release of Tns from CMC in non-ischemic extra-cardiac pathologies, mechanisms of circulation and elimination of Tns from the human body, mechanisms of transport of Tns to other biological fluids and factors that may affect these processes have not been established. In this comprehensive manuscript, all stages of the metabolic pathway are consistently and in detail considered, starting from release from CMC and ending with excretion (removal) from the human body. In addition, the possible diagnostic role of individual stages and mechanisms, influencing factors is analyzed and directions for further research in this area are noted.

show abstract

“…Determination of erythropoietin in amniotic fluid is a useful investigation. However, other pathological conditions can contribute to aberrations in levels of amniotic erythropoietin (such as parvo virus B19 infection [3] and hypoxia [4]). …”

mentioning

confidence: 99%

Erythropoietin in amniotic fluid

Joob¹,

Wiwanitkit

2014

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

Analysis about the influence on the fetus infected with parvovirus B19 using amniotic erythropoietin and troponin-T

Abstract: The study has determined an amniotic Epo level of ≥50 mU/ml as a factor of the influence on the fetus infected with PB19. The measurement of amniotic Epo level combined with amniotic TnT level is effective for determining the severity of fetal hypoxia.

Cited by 7 publications

References 16 publications

Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta‐analysis

Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta‐analysis

Metabolic Pathway of Cardiospecific Troponins: From Fundamental Aspects to Diagnostic Role (Comprehensive Review)

Erythropoietin in amniotic fluid

Contact Info

Product

Resources

About